Anthem Biosciences Limited (NSE:ANTHEM)
869.50
-5.00 (-0.57%)
Aug 21, 2026, 3:29 PM IST
Anthem Biosciences Revenue
Anthem Biosciences had revenue of 4.18B INR in the quarter ending June 30, 2026, a decrease of -22.58%. This brings the company's revenue in the last twelve months to 20.07B, down -2.18% year-over-year. In the fiscal year ending March 31, 2026, Anthem Biosciences had annual revenue of 21.29B with 15.09% growth.
Revenue (ttm)
20.07B
Revenue Growth
-2.18%
P/S Ratio
24.45
Revenue / Employee
8.80M
Employees
2,282
Market Cap
490.80B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 21.29B | 2.79B | 15.09% |
| Mar 31, 2025 | 18.50B | 4.30B | 30.28% |
| Mar 31, 2024 | 14.20B | 3.62B | 34.24% |
| Mar 31, 2023 | 10.58B | -1.83B | -14.74% |
| Mar 31, 2022 | 12.41B | 1.35B | 12.24% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Biocon | 173.21B |
| Dishman Carbogen Amcis | 29.01B |
| OneSource Specialty Pharma | 15.43B |
| Concord Biotech | 11.08B |
| Blue Jet Healthcare | 8.86B |
| Supriya Lifescience | 8.73B |
| Panacea Biotec | 6.73B |
| Zota Health Care | 6.09B |
Anthem Biosciences News
- 4 weeks ago - Anthem Biosciences Transcript: Q1 26/27 - Transcripts
- 4 weeks ago - Anthem Biosciences Quarterly report: Q1 2027 - Filings
- 4 weeks ago - Anthem Biosciences Slides: Q1 2027 - Filings
- 3 months ago - Anthem Biosciences Transcript: Q4 25/26 - Transcripts
- 3 months ago - Anthem Biosciences Quarterly report: Q4 2026 - Filings
- 3 months ago - Anthem Biosciences Slides: Q4 2026 - Filings
- 3 months ago - Anthem Biosciences Annual report: Q4 2026 - Filings
- 7 months ago - Anthem Biosciences Transcript: Q3 25/26 - Transcripts